We previously reported associations between intestinal inflammation and the NLRP3 inflammasome (10), suggesting that the development of NLRP3-targeted therapeutics may hold promise in mitigating enteritis during MTX chemotherapy. This evidence concerns the gene NLRP3 and enteritis.